Phaseline

Targets › EGLN1

EGLN1 (Egl nine homolog 1): drug programs, companies and trials

5 programs from 5 companies in 9 trials: 3 Phase 3, 3 Phase 4, 2 Phase 1, 1 Phase 2; Genitourinary, Hematology, Psychiatry; next expected readout Oct 2027.

Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A. Also hydroxylates HIF2A. Has a preference for the CODD site for both HIF1A and HIF1B. Hydroxylated HIFs…. (UniProt, Q9GZT9)

Open in Phaseline: the race on EGLN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Zhongshan HospitalEnarodustat
Egl nine homolog 1 inhibitor
EGLN1Phase 4Chronic Kidney Disease Associated AnemiaJan 2029
Zydus LifesciencesDesidustat
PHD inhibitor
EGLN1, EGLN2, EGLN3Phase 4Chronic Kidney Diseases–
AstellasRoxadustat
Hypoxia-inducible factor prolyl hydroxylase inhibitor
EGLN2, P4HTM, EGLN1, EGLN3Phase 3Chronic Kidney Disease; Dialysis; Complications; Perioperative Anemia; Kidney Failure, Chronic …Oct 2027
USRC Kidney ResearchVadadustat
Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor
EGLN1, EGLN3, EGLN2Phase 3Anemia of Chronic Kidney Disease–
Paul PotnuruVadadustat
Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor
EGLN1, EGLN3, EGLN2Phase 2Nonintubated Acute Respiratory Distress Syndrome (ARDS)May 2031

Conditions

Chronic Kidney Disease (1) Dialysis; Complications (1) Perioperative Anemia (1) Kidney Failure, Chronic (1) Kidney Failure,Chronic (1) Anemia of Chronic Kidney Disease (1) Chronic Kidney Diseases (1) Chronic Kidney Disease Associated Anemia (1) Nonintubated Acute Respiratory Distress Syndrome (ARDS) (1)

Modalities

small molecule (4), mixed (1)

Companies

Astellas (1) USRC Kidney Research (1) Zydus Lifesciences (1) Shanghai Zhongshan Hospital (1) Paul Potnuru (1)

Related targets

EGLN2 (4) EGLN3 (4) P4HTM (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.